IL6 Modulates the Immune Status of the Tumor Microenvironment to Facilitate Metastatic Colonization of Colorectal Cancer Cells

被引:70
作者
Toyoshima, Yujiro [1 ,2 ]
Kitamura, Hidemitsu [1 ]
Xiang, Huihui [1 ,2 ]
Ohno, Yosuke [2 ]
Homma, Shigenori [2 ]
Kawamura, Hideki [2 ]
Takahashi, Norihiko [2 ]
Kamiyama, Toshiya [2 ]
Tanino, Mishie [3 ]
Taketomi, Akinobu [2 ]
机构
[1] Hokkaido Univ, Inst Med Genet, Div Funct Immunol, Sect Dis Control, Sapporo, Hokkaido, Japan
[2] Hokkaido Univ, Grad Sch Med, Dept Gastroenterol Surg 1, Sapporo, Hokkaido, Japan
[3] Asahikawa Med Univ, Dept Surg Pathol, Asahikawa, Hokkaido, Japan
基金
日本学术振兴会;
关键词
LIGAND; 1; EXPRESSION; DENDRITIC CELLS; PD-L1; IFN-GAMMA; IN-VIVO; IL-6; INTERLEUKIN-6; RECEPTOR; LYMPHOCYTES; ANTIBODY;
D O I
10.1158/2326-6066.CIR-18-0766
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
It is unknown as to how liver metastases are correlated with host immune status in colorectal cancer. In this study, we found that IL6, a proinflammatory cytokine produced in tumor-bearing states, promoted the metastatic colonization of colon cancer cells in association with dysfunctional antitumor immunity. In IL6-deficient mice, metastatic colonization of CT26 cells in the liver was reduced, and the antitumor effector function of CD8(+) T cells, as well as IL12 production by CD11c(+) dendritic cells, were augmented in vivo. IL6-deficient mice exhibited enhanced IFN-AR1-mediated type I interferon signaling, which upregulated PD-L1 and MHC class I expression on CT26 cells. In vivo injection of anti-PD-L1 effectively suppressed the metastatic colonization of CT26 cells in Il6(-/-) but not in Il6(+/+) mice. Finally, we confirmed that colorectal cancer patients with low IL6 expression in their primary tumors showed prolonged disease-free survival. These findings suggest that IL6 may be a promising target for the treatment of metastasis in colorectal cancers by improving host immunity.
引用
收藏
页码:1944 / 1957
页数:14
相关论文
共 51 条
[1]   IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer [J].
Abiko, K. ;
Matsumura, N. ;
Hamanishi, J. ;
Horikawa, N. ;
Murakami, R. ;
Yamaguchi, K. ;
Yoshioka, Y. ;
Baba, T. ;
Konishi, I. ;
Mandai, M. .
BRITISH JOURNAL OF CANCER, 2015, 112 (09) :1501-1509
[2]   The ETS factor ESE3/EHF represses IL-6 preventing STAT3 activation and expansion of the prostate cancer stem-like compartment [J].
Albino, Domenico ;
Civenni, Gianluca ;
Rossi, Simona ;
Mitra, Abhishek ;
Catapano, Carlo V. ;
Carbone, Giuseppina M. .
ONCOTARGET, 2016, 7 (47) :76756-76768
[3]   Global patterns and trends in colorectal cancer incidence and mortality [J].
Arnold, Melina ;
Sierra, Monica S. ;
Laversanne, Mathieu ;
Soerjomataram, Isabelle ;
Jemal, Ahmedin ;
Bray, Freddie .
GUT, 2017, 66 (04) :683-691
[4]   Understanding the tumor immune microenvironment (TIME) for effective therapy [J].
Binnewies, Mikhail ;
Roberts, Edward W. ;
Kersten, Kelly ;
Chan, Vincent ;
Fearon, Douglas F. ;
Merad, Miriam ;
Coussens, Lisa M. ;
Gabrilovich, Dmitry I. ;
Ostrand-Rosenberg, Suzanne ;
Hedrick, Catherine C. ;
Vonderheide, Robert H. ;
Pittet, Mikael J. ;
Jain, Rakesh K. ;
Zou, Weiping ;
Howcroft, T. Kevin ;
Woodhouse, Elisa C. ;
Weinberg, Robert A. ;
Krummel, Matthew F. .
NATURE MEDICINE, 2018, 24 (05) :541-550
[5]   Liver resection for metastatic colorectal cancer in the presence of extrahepatic disease [J].
Carpizo, Darren R. ;
D'Angelica, Michael .
LANCET ONCOLOGY, 2009, 10 (08) :801-809
[6]   IFN gene/cell therapy curbs colorectal cancer colonization of the liver by acting on the hepatic microenvironment [J].
Catarinella, Mario ;
Monestiroli, Andrea ;
Escobar, Giulia ;
Fiocchi, Amleto ;
Ngoc Lan Tran ;
Aiolfi, Roberto ;
Marra, Paolo ;
Esposito, Antonio ;
Cipriani, Federica ;
Aldrighetti, Luca ;
Iannacone, Matteo ;
Naldini, Luigi ;
Guidotti, Luca G. ;
Sitia, Giovanni .
EMBO MOLECULAR MEDICINE, 2016, 8 (02) :155-170
[7]   Elements of cancer immunity and the cancer-immune set point [J].
Chen, Daniel S. ;
Mellman, Ira .
NATURE, 2017, 541 (7637) :321-330
[8]   Inflammation and cancer: advances and new agents [J].
Crusz, Shanthini M. ;
Balkwill, Frances R. .
NATURE REVIEWS CLINICAL ONCOLOGY, 2015, 12 (10) :584-596
[9]   Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma [J].
Darb-Esfahani, Silvia ;
Kunze, Catarina Alisa ;
Kulbe, Hagen ;
Sehouli, Jalid ;
Wienert, Stephan ;
Lindner, Judith ;
Budczies, Jan ;
Bockmayr, Michael ;
Dietel, Manfred ;
Denkert, Carsten ;
Braicu, Ioana ;
Joehrens, Korinna .
ONCOTARGET, 2016, 7 (02) :1486-1499
[10]   A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancer [J].
Dijkgraaf, E. M. ;
Santegoets, S. J. A. M. ;
Reyners, A. K. L. ;
Goedemans, R. ;
Wouters, M. C. A. ;
Kenter, G. G. ;
van Erkel, A. R. ;
van Poelgeest, M. I. E. ;
Nijman, H. W. ;
van der Hoeven, J. J. M. ;
Welters, M. J. P. ;
van der Burg, S. H. ;
Kroep, J. R. .
ANNALS OF ONCOLOGY, 2015, 26 (10) :2141-2149